InMed Pharmaceuticals Free Cash Flow (FCF) History (INM)

InMed Pharmaceuticals reported −$7.0M in free cash flow for fiscal 2024, an increase of $448,088 from the previous fiscal year, with a free cash flow margin of −152.14%.

View full InMed Pharmaceuticals company overview

InMed Pharmaceuticals free cash flow by year

InMed Pharmaceuticals annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20242024-06-30−$7.0M$448,088−152.14%
20232023-06-30−$7.4M$8.2M−544.99%
20222022-06-30−$15.6M−$5.8M−1143.90%
20212021-06-30−$9.8M−$2.4M−514.30%
20202020-06-30−$7.4M

InMed Pharmaceuticals free cash flow growth trends

InMed Pharmaceuticals's latest reported quarter, Q3 2024, generated −$1.9M in free cash flow, an increase of $969,593 year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review InMed Pharmaceuticals filings at SEC.gov ↗